Home >> Behavioral Health >> Behavioral Health >> Baby Food >> Technology & Media >>

Biogen Idec Inc. - Product Pipeline Review - 2013

Published: Sep-2013 | Format: PDF | Global Markets Direct | Number of pages: 76 | Code: MRS - 823

Global Market Directs pharmaceuticals report, Biogen Idec Inc. Product Pipeline Review 2013 provides data on the Biogen Idec Inc.s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Directs proprietary databases, Biogen Idec Inc.s corporate website, SEC filings, investor presentations and featured press releases, both from Biogen Idec Inc. and industry-specific third party sources, put together by Global Markets Directs team.

Scope

Biogen Idec Inc. Brief Biogen Idec Inc. overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of Biogen Idec Inc. human therapeutic division.
Overview of pipeline therapeutics across various therapy areas.
Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
Product profiles for late stage and clinical stage products of Biogen Idec Inc. with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones.
Recent updates of the Biogen Idec Inc.s pipeline in the last quarter.
Key discontinued and dormant projects.
Latest news and deals relating to the products.

Reasons to buy

Evaluate Biogen Idec Inc.s strategic position with total access to detailed information on its product pipeline.
Assess the growth potential of Biogen Idec Inc. in its therapy areas of focus.
Identify new drug targets and therapeutic classes in the Biogen Idec Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
Exploit collaboration and partnership opportunities with Biogen Idec Inc..
Avoid Intellectual Property Rights related issues.
Explore the dormant and discontinued projects of Biogen Idec Inc. and identify potential opportunities in those areas.

Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 6
Biogen Idec Inc. Snapshot 7
Biogen Idec Inc. Overview 7
Key Information 7
Key Facts 7
Biogen Idec Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Biogen Idec Inc. - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Biogen Idec Inc. - Pipeline Products Glance 14
Biogen Idec Inc. - Late Stage Pipeline 14
Phase III Products/Combination Treatment Modalities 14
Biogen Idec Inc. Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Biogen Idec Inc. - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Biogen Idec Inc. - Drug Profiles 19
aducanumab 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Alpha Synuclein Program 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Antibodies For Amyotrophic Lateral Sclerosis 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
BG-00001 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
BG-00010 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
BIIB-021 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
BIIB-022 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
BIIB-023 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
BIIB-028 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
BIIB-029 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
BIIB-031 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
BIIB-033 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
BIIB-034 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
BIIB-053 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
BIIB-054 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
dimethyl fumarate 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Gamma Secretase Modulator 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
natalizumab 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NI-105 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
peginterferon beta-1a 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Peptide Mimetic 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
rFVIII 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
rituximab 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
TDP-43 Program 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Biogen Idec Inc. - Pipeline Analysis 43
Biogen Idec Inc. - Pipeline Products by Therapeutic Class 43
Biogen Idec Inc. - Pipeline Products By Target 46
Biogen Idec Inc. - Pipeline Products by Route of Administration 47
Biogen Idec Inc. - Recent Pipeline Updates 48
Biogen Idec Inc. - Dormant Projects 65
Biogen Idec Inc. - Discontinued Pipeline Products 67
Discontinued Pipeline Product Profiles 67
baminercept alfa 67
clenoliximab 67
CNF-1010 67
dexpramipexole dihydrochloride 68
naxifylline 68
vipadenant 68
Biogen Idec Inc. - Company Statement 69
Biogen Idec Inc. - Locations And Subsidiaries 70
Head Office 70
Other Locations & Subsidiaries 70
Biogen Idec Inc. - Key Manufacturing Facilities 74

Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76


List of Tables


Biogen Idec Inc., Key Information 7
Biogen Idec Inc., Key Facts 7
Biogen Idec Inc. - Pipeline by Indication, 2013 10
Biogen Idec Inc. - Pipeline by Stage of Development, 2013 12
Biogen Idec Inc. - Monotherapy Products in Pipeline, 2013 13
Biogen Idec Inc. - Phase III, 2013 14
Biogen Idec Inc. - Phase II, 2013 15
Biogen Idec Inc. - Phase I, 2013 16
Biogen Idec Inc. - Preclinical, 2013 17
Biogen Idec Inc. - Discovery, 2013 18
Biogen Idec Inc. - Pipeline By Therapeutic Class, 2013 44
Biogen Idec Inc. - Pipeline By Target, 2013 46
Biogen Idec Inc. - Pipeline By Route of Administration, 2013 47
Biogen Idec Inc. - Recent Pipeline Updates, 2013 48
Biogen Idec Inc. - Dormant Developmental Projects,2013 65
Biogen Idec Inc. - Discontinued Pipeline Products, 2013 67
Biogen Idec Inc., Other Locations 70
Biogen Idec Inc., Subsidiaries 70
Biogen Idec Inc., Key Manufacturing Facilities 74 

List of Figures

Biogen Idec Inc. - Pipeline by Indication, 2013 10
Biogen Idec Inc. - Pipeline by Stage of Development, 2013 12
Biogen Idec Inc. - Monotherapy Products in Pipeline, 2013 13
Biogen Idec Inc. - Pipeline By Therapeutic Class, 2013 43
Biogen Idec Inc. - Pipeline By Route of Administration, 2013 47 

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing